文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

供受者性别相容性对血液系统恶性肿瘤患者单倍体造血干细胞移植结局的影响

[The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

回顾性分析648例接受基于ATG和单纯外周血干细胞来源单倍体造血干细胞移植的恶性血液病患者,探讨供受者性别组合对移植结局的影响。结果显示供受者性别组合对主要临床结局无显著影响,但女供男模式与较低的28天累积血小板植入率及血小板植入延迟相关。

要点

  • 供受者性别相合与不合组间主要移植结局差异无统计学意义。
  • 女供男组28天累积血小板植入率低于男供女组和女供女组。
  • 女供男组在ATG-F 10 mg/kg方案下血小板植入率低于其他组。

核心结论

  • 在基于ATG和PBSC来源的单倍体造血干细胞移植模式下,供受者性别组合对恶性血液病患者移植后主要临床结局没有影响。
  • 女供男模式与血小板植入延迟和较低的移植后28天累积血小板植入率相关。

研究设计与样本

  • 回顾性分析2015年2月至2020年9月在浙江大学医学院附属第一医院骨髓移植中心接受清髓性单倍体造血干细胞移植的648例恶性血液病患者。
  • 男363例(56.0%),女285例(44.0%),中位年龄32(14~62)岁。
  • 疾病类型:急性淋巴细胞白血病242例(37.3%),急性髓系白血病293例(45.2%),骨髓增生异常综合征56例(8.7%),非霍奇金淋巴瘤27例(4.2%),其他恶性血液病30例(4.6%)。

主要发现

  • 全集3年总生存率为(73.10±1.90)%,无病生存率为(70.80±1.90)%,Ⅱ~Ⅳ度急性GVHD累积发生率为(33.96±1.87)%,Ⅲ/Ⅳ度急性GVHD为(13.08±1.33)%。
  • 全集3年中/重度慢性GVHD累积发生率为(35.10±2.14)%,重度慢性GVHD为(10.66±1.38)%,累积复发率为(19.43±1.67)%,非复发死亡率为(9.80±1.24)%。
  • 供受者性别相合与不合组间28天累积中性粒细胞植入率(P=0.270)、血小板植入率(P=0.842)及Ⅱ~Ⅳ度、Ⅲ/Ⅳ度急性GVHD、3年OS、DFS、累积复发率、NRM、慢性GVHD累积发生率差异均无统计学意义(P>0.05)。
  • 女供男组28天累积血小板植入率[(91.45±2.63)%]低于男供女组[(94.77±1.75)%,P=0.004]和女供女组[(95.54±2.05)%,P=0.005],与男供男组[(95.08±1.41)%,P=0.284]差异无统计学意义。
  • 女供男组28天累积血小板植入率低于其他组[(91.45±2.63)%对(95.08±0.95)%,P=0.037];在ATG-F 10 mg/kg方案中女供男组低于其他组[(89.29±4.29)%对(94.49±1.45)%,P=0.037],在rATG-T 6 mg/kg方案中差异无统计学意义[(93.44±3.38)%对(95.62±1.26)%,P=0.404]。

关键数值与推荐

  • ≤35岁患者中,姐妹供者组与兄弟供者组3年重度慢性GVHD累积发生率分别为(26.71±5.90)%与(10.33±4.43)%(P=0.054)。
  • >35岁患者中,女儿供者组与儿子供者组3年中重度慢性GVHD累积发生率分别为(40.07±6.65)%与(27.41±4.54)%(P=0.084)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate how gender differences between the donor and the recipient affect the effectiveness of antithymocyte globulin (ATG) and pure peripheral blood stem cell (PBSC) hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of malignant hematological diseases. Methods: From February 2015 to September 2020, 648 hematological malignancies patients underwent myeloablative condition regimen haplo-HSCT treatment at the Bone Marrow Transplant Center of the First Affiliated Hospital of Zhejiang University. The median age was 32 (14-62) years, with 363 males (56.0% ) and 285 females (44.0% ) present. 242 cases of acute lymphoblastic leukemia (ALL) (37.3% ) , 293 cases of acute myeloid leukemia (AML) (45.2% ) , 56 cases of myelodysplastic syndrome (MDS) (8.7% ) , 27 cases of non-Hodgkin's lymphoma (NHL) (4.2% ) , and 30 cases of other hematological malignancies (4.6% ) . Results: ① The 3-year overall survival (OS) , DFS, the incidence of Ⅱ-Ⅳ grade acute graft-versus-host disease (aGVHD) , the incidence of Ⅲ-Ⅳ grade aGVHD, the 3-year incidence of moderate & severe chronic GVHD (cGVHD) , severe cGVHD, the 3-year incidence of relapse, and NRM of the whole group were (73.10±1.90) % , (70.80±1.90) % , (33.96±1.87) % , (13.08±1.33) % , (35.10±2.14) % , (10.66±1.38) % , (19.43±1.67) % , and (9.80±1.24) % , respectively. ②There was no statistically significant difference between the donor-recipient gender match and donor-recipient gender mismatch groups in the 28-day cumulative neutrophil engraftment rate, 28-day cumulative platelet engraftment rate, the incidence of Ⅱ-Ⅳ grade aGVHD, the incidence of Ⅲ-Ⅳ grade aGVHD, 3-year OS, 3-year DFS, the cumulative incidence of relapse, NRM, and incidence of moderate & severe cGVHD, severe cGVHD. ③The 28-day cumulative neutrophil engraftment rate did not differ statistically between the male-female, female-female, male-male, and female-male groups (P=0.148) . The incidence of Ⅱ-Ⅳ grade aGVHD, the incidence of Ⅲ-Ⅳ grade aGVHD, 3-year OS, 3-year DFS, cumulative relapse rate, and NRM, and the incidence of cGVHD were not statistically different among the four groups (P>0.05) . The 28-day cumulative platelet engraftment rate of the female-male group was significantly lower than male-female group, and the female-female group [ (91.45±2.63) % vs. (94.77±1.75) % , P=0.004; (91.45±2.63) % vs. (95.54±2.05) % , P=0.005]. No significant difference existed in the 28-day cumulative platelet engraftment rate between the female-male group and the male-male group [ (91.45±2.63) % vs. (95.08±1.41) % , P=0.284]. ④Among patients ≤35 years old, the 3-year incidence of severe cGVHD patients receiving sister donors and sibling donors were (26.71±5.90) % and (10.33±4.43) % , respectively (P=0.054) . Patients accepting daughter donors and son donors had a 3-year incidence of moderate and severe cGVHD that was 40.07% vs. 27.41% , respectively, among those over 35 (40.07±6.65) % vs. (27.41±4.54) % (P=0.084) . ⑤Female donors to male recipients had a significantly lower 28-day cumulative platelet engraftment rate compared to the other groups [ (91.45±2.63) % vs. (95.08±0.95) % , P=0.037]. ⑥ Female donors to male recipients had a significantly lower 28-day cumulative platelet engraftment rate than the other groups in the ATG-Fresenius (ATG-F) 10 mg/kg group [ (89.29±4.29) % vs. (94.49±1.45) % , P=0.037]. But when compared to the other groups in the Rabbit Antihuman Thymocyte Immunoglobulin (rATG-T) 6 mg/kg group, the 28-day cumulative platelet implantation rate between female donors and male recipients was not significantly different [ (93.44±3.38) % vs. (95.62±1.26) % , P=0.404]. Conclusion: The main clinical outcomes of patients with malignant blood diseases following transplantation are unaffected by the gender combination of the donor and patient in the haplo-HSCT mode based on ATG and PBSC sources. Female donors to male recipients have a lower 28-day cumulative platelet engraftment rate and longer platelet engraftment times. 目的: 探究供患者性别组合对基于抗胸腺细胞球蛋白(ATG)和单纯外周血干细胞(PBSC)来源单倍体造血干细胞移植(haplo-HSCT)治疗恶性血液病移植结局的影响。 方法: 对2015年2月至2020年9月在浙江大学医学院附属第一医院骨髓移植中心接受清髓性haplo-HSCT的648例恶性血液病患者进行回顾性分析。男363例(56.0%),女285例(44.0%),中位年龄32(14~62)岁。急性淋巴细胞白血病(ALL)242例(37.3%),急性髓系白血病(AML)293例(45.2%),骨髓增生异常综合征(MDS)56例(8.7%),非霍奇金淋巴瘤(NHL)27例(4.2%),其他恶性血液病30例(4.6%)。 结果: ①所有患者移植后3年总生存(OS)率为(73.10±1.90)%,无病生存(DFS)率为(70.80±1.90)%,Ⅱ~Ⅳ度、Ⅲ/Ⅳ度急性移植物抗宿主病(GVHD)累积发生率分别为(33.96±1.87)%、(13.08±1.33)%,3年中/重度慢性GVHD、重度慢性GVHD累积发生率分别为(35.10±2.14)%、(10.66±1.38)%,累积复发率(CIR)为(19.43±1.67)%,非复发死亡率(NRM)为(9.80±1.24)%。②供患者性别相合、性别不合组haplo-HSCT后28 d累积中性粒细胞植入率、血小板植入率差异无统计学意义(P=0.270,P=0.842),Ⅱ~Ⅳ度、Ⅲ/Ⅳ度急性GVHD累积发生率及移植后3年OS率、DFS率、CIR、NRM率、慢性GVHD累积发生率差异均无统计学意义(P>0.05)。③男供女、女供女、男供男、女供男组haplo-HSCT后28 d累积中性粒细胞植入率差异无统计学意义(P=0.148),Ⅱ~Ⅳ度、Ⅲ/Ⅳ度急性GVHD累积发生率及移植后3年OS率、DFS率、CIR、NRM、慢性GVHD累积发生率差异均无统计学意义(P>0.05)。女供男组移植后28 d累积血小板植入率[(91.45±2.63)%]低于男供女组[(94.77±1.75)%,P=0.004]、女供女组[(95.54±2.05)%,P=0.005],与男供男组[(95.08±1.41)%,P=0.284]比较差异无统计学意义。④在≤35岁患者中,姐妹供者组、兄弟供者组移植后3年重度慢性GVHD累积发生率分别为(26.71±5.90)%、(10.33±4.43)%(P=0.054);在>35岁患者中,女儿供者组、儿子供者组移植后3年中重度慢性GVHD累积发生率分别为(40.07±6.65)%、(27.41±4.54)%(P=0.084)。⑤女供男组移植后28 d累积血小板植入率低于其他组[(91.45±2.63)%对(95.08±0.95)%,P=0.037]。⑥抗人T细胞兔免疫球蛋白10 mg/kg预防GVHD方案女供男组的28 d累积血小板植入率低于其他组[(89.29±4.29)%对(94.49±1.45)%,P=0.037],兔抗人胸腺细胞球蛋白6 mg/kg预防GVHD方案女供男组与其他组移植后28 d累积血小板植入率差异无统计学意义[(93.44±3.38)%对(95.62±1.26)%,P=0.404]。 结论: 在基于ATG和PBSC来源的haplo-HSCT模式下,供患者性别组合对恶性血液病患者haplo-HSCT后主要临床结局没有影响。女供男模式与血小板植入延迟和较低的移植后28 d累积血小板植入率相关。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Hu SS, Wu YB, Zhu PP, et al. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709104. doi:10.3760/cma.j.issn.0253-2727.2022.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。